The top 20 pharmaceutical companies have implemented a raft of new initiatives in the last two years. Yet in two important areas, progress remains static.

› Go to Key Findings

The industry pipeline is concentrated on five diseases. Five companies are developing more than half the products for developing countries.

› Go to Key Findings

Half of the companies in the Index are developing medicines tailored for children, with 7% of the overall research pipeline being devoted to “child-size” medicine.

› Go to Key Findings

More companies are tailoring their prices to different segments of national populations.

› Go to Key Findings

Home

Analysis Highlights

Download the report

Download the report

2014 Index Ranking

Latest News

2015 Methodology Review: targeting key aspects of the Index analysis

13 May 2015 |
The Access to Medicine Foundation is now reviewing the Index methodology in preparation for the next Access to Medicine Index. With stakeholder engagement as a central pillar, the 2015 Methodology Review focuses on key aspects of the Index analysis. › Read more

Access to Vaccines Index: introducing the first principles

12 May 2015 |
The Access to Medicine Foundation has started the development of a new Index, focused exclusively on vaccines. It will measure and compare the efforts of vaccine manufacturers to make vaccines accessible for people living in developing countries.› Read more

New Research: How pharmaceutical companies address access to maternal and reproductive health

9 April 2015 |
Every day, an estimated 800 women die during pregnancy and childbirth due to preventable causes. Today, the Access to Medicine Foundation publishes the first landscape study of pharmaceutical companies’ responses to MDG 5 to help improve this situation.› Read more

April 9: WHO seminar on Access to Medicine Index; BioPharma Sustainability Roundtable

31 March 2015 |
In April, representatives of the Access to Medicine Foundation have been invited to lead a WHO seminar in Geneva and speak at the BioPharma Sustainability Roundtable in Cambridge, USA.› Read more

Pharma companies discuss 2014 Index performances

10 February 2015 |
The 2014 Access to Medicine Index identifies clear opportunities for pharmaceutical companies to improve access to their products. During a month of individual evaluation sessions, companies and the Index team discuss how to make the most of their potential.› Read more

What Leaders Say

Dr. Margaret Chan
Director-General, World Health Organization
"The Access to Medicine Index is a very important project. What gets measured, gets done."
Bill Gates
Chairman of Microsoft Corporation, Co-Chair and Trustee of the Bill & Melinda Gates Foundation
"When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that."
Justine Greening
Justine Greening
The Rt Hon Justine Greening MP, Secretary of State for International Development, UK
This year’s index shows that the pharmaceutical industry has made progress in improving access to vital medicines for the globe’s poorest people, helping to tackle some of the world’s worst diseases. The deadly Ebola outbreak reminds us that there is still much to be done to stop the spread of diseases in developing countries.
Lilianne Ploumen
Minister for Foreign Trade and Development Cooperation, the Netherlands
“The Access to Medicine Index mobilizes the strength of the private sector, impacting the lives of millions of the most vulnerable people on earth. It showcases the synergy of aid, trade and investment.”
Knut Kjaer
Former CEO of RiskMetrics Group, Former CEO of Norges Bank Investment Management (NBIM) (1997-2007)
"Companies are beginning to understand that the value of corporate social responsibility programmes is not only the opportunity to do the right thing but that it's good for business as well. The Access to Medicine Index provides companies with a chance to improve performance and explore new business models while helping societies in need."

In the Media

Jay Iyer on Danish pharma companies in Politiken

19 April 2015 |

Danish newspaper Politiken publishes a piece by Jayasree K. Iyer, the Index's Head of Research, and Damiano de Felice, Strategy.

› Read more

Jay Iyer on Swiss Index companies in Le Temps

12 March 2015 |

Writing in Le Temps, Index team members Damiano de Felice and Jayasree K. Iyer (Head of Research) give an overview of how Swiss policy and Swiss pharmaceutical companies are addressing access to medicine.

› Read more

2014 Index findings in the Pharmaceutical Journal

19 January 2015 |

The Pharmaceutical Journal in London creates an infographic of a range of findings from the 2014 Access to Medicine Index, including insights into the development of innovative and adapted products, equitable pricing strategies and local capacity building initiatives.

› Read more

Tara Prasad comments on vaccine pricing in De Volkskrant

27 January 2015 |

Writing in Dutch national newspaper De Volkskrant, Lisa Koetsenruijter covers the rises in vaccine prices over recent years.

› Read more

Wim Leereveld on BNR News Radio (Dutch)

19 January 2015 |

In a detailed 30-minute interview, Wim Leereveld talks to Paul van Liempt about how the Access to Medicine Index has evolved since its beginnings in 2003, and about the role it now plays in stimulating global pharmaceutical companies to help change the world.

› Read more